Neuropathic pain in cancer patients is often difficult to treat, requiring a combination of several different pharmacological therapies. We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but responded dramatically to the addition of levorphanol. Levorphanol is a synthetic strong opioid that is a potent N-methyl-d-aspartate receptor antagonist, mu, kappa, and delta opioid receptor agonist, and reuptake inhibitor of serotonin and norepinephrine. It bypasses hepatic first-pass metabolism and thereby not subjected to numerous drug interactions. Levorphanol's unique profile makes it a potentially attractive opioid in cancer pain management.
Get full access to this article
View all access options for this article.
References
1.
RobertoA, DeandreaS, GrecoMT, et al.: Prevalence of neuropathic pain in cancer patients: Pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian Palliative Care Centers. J Pain Symptom Manage, 2016; 51:1091.e4–1102.e4.
2.
CaraceniA, PortenoyRK: An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain, 1999; 82:263–274.
3.
HershmanDL, LacchettiC, DworkinRH, et al.: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2014; 32:1941–1967.
4.
PianoV, VerhagenS, SchalkwijkA, et al.: Treatment for neuropathic pain in patients with cancer: Comparative analysis of recommendations in national clinical practice guidelines from European countries. Pain Pract, 2014; 14:1–7.
5.
BoogaardS, HeymansMW, de VetHC, et al.: Predictors of persistent neuropathic pain—A systematic review. Pain physician, 2015; 18:433–457.
6.
SmithEM, PangH, CirrincioneC, et al.: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA, 2013; 309:1359–1367.
7.
PachmanDR, WatsonJC, LoprinziCL: Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr Treat Options Oncol, 2014; 15:567–580.
8.
LuoY, AndersonTA: Phantom limb pain: A review. Int Anesthesiol Clin, 2016; 54:121–139.
MendozaJE: Brown-Séquard syndrome. In: KreutzerJS, DeLucaJ, CaplanB, eds. Encyclopedia of Clinical Neuropsychology. New York, NY: Springer New York, 2011, pp. 460–460.
14.
SahgalA, MaL, GibbsI, et al.: Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol, 2010; 77:548–553.
15.
GersztenPC, BurtonSA, OzhasogluC, et al.: Radiosurgery for benign intradural spinal tumors. Neurosurgery, 2008; 62:887–895; discussion 895–886.
16.
PsimarasD, TafaniC, DucrayF, et al.: Bevacizumab in late-onset radiation-induced myelopathy. Neurology, 2016; 86:454–457.
17.
Karadag-SaygiE, Cubukcu-AydoseliK, AydoseliA, AkyuzG: Brown-Sequard syndrome caused by cervical disc herniation: Case report and review. Neurosurg Quart, 2010; 20:46–47.
18.
GlantzMJ, BurgerPC, FriedmanAH, et al.: Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology, 1994; 44:2020–2027.
19.
BrueraE, KuehnN, MillerMJ, et al.: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care, 1991; 7:6–9.
20.
FinnerupNB, AttalN, HaroutounianS, et al.: Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol, 2015; 14:162–173.
21.
BennettMI: Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: Systematic review. Palliat Med, 2011; 25:553–559.
22.
FainsingerRL, NekolaichukC, LawlorP, et al.: An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer, 2010; 46:2896–2904.
23.
BrunelliC, KaasaS, KnudsenAK, et al.: Comparisons of patient and physician assessment of pain-related domains in cancer pain classification: Results from a large international multicenter study. J Pain, 2014; 15:59–67.
24.
FallonMT: Neuropathic pain in cancer. BJA, 2013; 111:105–111.
25.
KnudsenAK, BrunelliC, KlepstadP, et al.: Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain, 2012; 153:696–703.
26.
ChernyNI, ThalerHT, Friedlander-KlarH, et al.: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology, 1994; 44:857–861.
27.
CaraceniA, HanksG, KaasaS, et al.: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol, 2012; 13:e58–e68.
StringerM, MakinMK, MilesJ, MorleyJS: d-Morphine, but not l-morphine, has low micromolar affinity for the non-competitive N-Methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neurosci Lett, 2000; 295:21–24.
30.
CoddEE, ShankRP, SchupskyJJ, RaffaRB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther, 1995; 274:1263–1270.
31.
PhamTC, FudinJ, RaffaRB: Is levorphanol a better option than methadone?. Pain Med, 2015; 16:1673–1679.
32.
PrommerE: Levorphanol: Revisiting an underutilized analgesic. Palliat Care, 2014; 8:7–10.
33.
McNultyJPMFF: Levorphanol for excruciating pain from oral cancer: A case report. Int J Pharm Compd, 2007; 11:212–218.
34.
McNultyJP: Can levorphanol be used like methadone for intractable refractory pain?. J Palliat Med, 2007; 10:293–296.
35.
RowbothamMC, TwillingL, DaviesPS, et al.: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med, 2003; 348:1223–1232.
36.
ChapmanV, DickensonAH: The combination of NMDA antagonism and morphine produces profound antinociception in the rat dorsal horn. Brain Res, 1992; 573:321–323.
37.
PrommerE: Levorphanol: The forgotten opioid. Support Care Cancer, 2007; 15:259–264.
38.
RayWA, ChungCP, MurrayKT, et al.: Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med, 2015; 175:420–427.
39.
ChouR, CrucianiRA, FiellinDA, et al.Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain, 2014; 15:321–337.
